HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA)

Pancreatology

Volumn 12, Issue 2, 2012, Pages 146-155

  Mehdi, Ouaïssi ^a,b,c,f   Françoise, Silvy ^c   Sofia, Costa Lima ^d   Urs, Giger ^b,c   Kevin, Zemmour ^a,b   Bernard, Sastre ^a,b,c   Igor, Sielezneff ^a,b,c   Anabela, Cordeiro Da Silva ^d,e   Dominique, Lombardo ^a,c   Eric, Mas ^a,b,c   Ali, Ouaïssi ^c,d  

^a AIX MARSEILLE UNIVERSITY   (France)

^b TIMONE HOSPITAL   (France)

^c INSERM   (France)

^d UNIVERSITY OF PORTO   (Portugal)

^e UNIVERSITY OF PORTO   (Portugal)

^f University of the Mediterranean Aix Marseille II   (France)

Author keywords

Apoptosis; BxPC 3 cells; Pancreatic cancer; Panobinostat; Xenograft tumor

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; DNA FRAGMENT; GEMCITABINE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 2; PANOBINOSTAT; PHOSPHATIDYLSERINE; SIRTUIN; SIRTUIN 1; STAUROSPORINE; TRICHOSTATIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE ARREST; CELL GROWTH; CELL IMMORTALIZATION; CELL VIABILITY; COLORIMETRY; CONTROLLED STUDY; CYTOTOXICITY; DNA FRAGMENTATION; DRUG EFFICACY; DRUG FORMULATION; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOASSAY; IN VIVO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREAS DUCT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TARGET CELL; TRANSCRIPTION INITIATION; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 84862163445     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1016/j.pan.2012.02.013     Document Type: Article

References (46)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 2000;2000(50):7-33.
2. Rosenberg L. Pancreatic cancer: a review of emerging therapies. Drugs 2000; 59:1071-89. (Pubitemid 30339131)
3. Burris 3rd HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as firstline therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13. (Pubitemid 27251144)
4. Crnogorac-Jurcevic T, Missiaglia E, Blaveri E, Gangeswaran R, Jones M, Terris B, et al. Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of s100 genes is highly prevalent. J Pathol 2003;201:63-74. (Pubitemid 37121204)
5. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, Adsay NV, Shen-Ong GL, Berg K, et al. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 2003;63: 8614-22. (Pubitemid 38064035)
6. Logsdon CD, Simeone DM, Binkley C, Arumugam T, Greenson JK, Giordano TJ, et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 2003;63:2649-57. (Pubitemid 36605209)
7. Grutzmann R, Pilarsky C, Ammerpohl O, Luttges J, Bohme A, Sipos B, et al. Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. Neoplasia 2004;6:611-22. (Pubitemid 39411099)
8. Cress WD, Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 2000;184:1-16. (Pubitemid 30349623)
9. Marks PA, Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 2001;13:477-83. (Pubitemid 33027900)
10. Timmermann S, Lehrmann H, Polesskaya A, Harel-Bellan A. Histone acetylation and disease. Cell Mol Life Sci 2001;58:728-36. (Pubitemid 32553030)
11. Annunziato AT, Hansen JC. Role of histone acetylation in the assembly and modulation of chromatin structures. Gene Expr 2000;9:37-61.
12. Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU, Joo HJ, et al. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 2001;92: 1300-4. (Pubitemid 34036893)
13. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M. Induction of hdac2 expression upon loss of apc in colorectal tumorigenesis. Cancer Cell 2004;5:455-63. (Pubitemid 38610247)
14. Wilson AJ, Byun DS, Popova N, Murray LB, L'Italien K, Sowa Y, et al. Histone deacetylase 3 (hdac3) and other class i hdacs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 2006;281:13548-58. (Pubitemid 43855268)
15. Scanlan MJ,Welt S,GordonCM, Chen YT, GureAO, Stockert E, et al. Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res 2002;62:4041-7. (Pubitemid 34791072)
16. de Nigris F, Cerutti J, Morelli C, Califano D, Chiariotti L, Viglietto G, et al. Isolation of a sir-like gene, sir-t8, that is overexpressed in thyroid carcinoma cell lines and tissues. Br J Cancer 2002;86:917-23. (Pubitemid 34271028)
17. Hiratsuka M, Inoue T, Toda T, Kimura N, Shirayoshi Y, Kamitani H, et al. Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of sirt2 gene. Biochem Biophys Res Commun 2003; 309:558-66. (Pubitemid 37083288)
18. Ouaissi M, Sielezneff I, Silvestre R, Sastre B, Bernard JP, Lafontaine JS, et al. High histone deacetylase 7 (hdac7) expression is significantly associated with adenocarcinomas of the pancreas. Ann Surg Oncol 2008;15:2318-28.
19. Acharya MR, Sparreboom A, Venitz J, Figg WD. Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol 2005;68:917-32. (Pubitemid 41345783)
20. Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, et al. A phase i study of intravenous lbh589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2006;12:4628-35. (Pubitemid 44297814)
21. Haefner M, Bluethner T, Niederhagen M, Moebius C, Wittekind C, Mossner J, et al. Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors. World J Gastroenterol 2008;14:3681-92.
22. Ouyang H, Mou L, Luk C, Liu N, Karaskova J, Squire J, et al. Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am J Pathol 2000;157:1623-31.
23. Qian J, Niu J, Li M, Chiao PJ, Tsao MS. In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by k-ras oncogenic activation in pancreatic carcinogenesis. Cancer Res 2005; 65:5045-53. (Pubitemid 40827312)
24. Ouaissi M, Cabral S, Tavares J, da Silva AC, Mathieu Daude F, Mas E, et al. Histone deacetylase (hdac) encoding gene expression in pancreatic cancer cell lines and cell sensitivity to hdac inhibitors. Cancer Biol Ther 2008;7:523-31. (Pubitemid 351847026)
25. Chow JY, Quach KT, Cabrera BL, Cabral JA, Beck SE, Carethers JM. Ras/erk modulates tgfbeta-regulated pten expression in human pancreatic adenocarcinoma cells. Carcinogenesis 2007;28:2321-7. (Pubitemid 350111590)
26. Furukawa T, Duguid WP, Rosenberg L, Viallet J, Galloway DA, Tsao MS. Longterm culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the e6-7 gene of human papilloma virus 16. Am J Pathol 1996;148:1763-70. (Pubitemid 26171674)
27. Moore PS, Sipos B, Orlandini S, Sorio C, Real FX, Lemoine NR, et al. Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of k-ras, p53, p16 and dpc4/smad4. Virchows Arch 2001;439:798-802. (Pubitemid 33141325)
28. Fujii Y, Sekiguchi M, Shiroko Y, Shimizu H, Sugawara I, Hasumi K, et al. Establishment and characterization of human pancreatic adenocarcinoma cell line soj producing carcinoembryonic antigen and carbohydrate antigen 19-9]. Hum Cell 1990;3:31-6.
29. Corpet F. Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res 1988;16:10881-90.
30. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-9.
31. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin v. J Immunol Methods 1995;184:39-51.
32. Scaduto Jr RC, Grotyohann LW. Measurement of mitochondrial membrane potential using fluorescent rhodamine derivatives. Biophys J 1999;76: 469-77. (Pubitemid 29202474)
33. Hoskins C, Ouaissi M, Lima SC, Cheng WP, Loureirio I, Mas E, et al. In vitro and in vivo anticancer activity of a novel nano-sized formulation based on selfassembling polymers against pancreatic cancer. Pharm Res 2010;27: 2694-703.
34. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase iii trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6.
35. Kindler HL. Pancreatic cancer: an update. Curr Oncol Rep 2007;9:170-6. (Pubitemid 46736349)
36. Philip PA. Targeted therapies for pancreatic cancer. Gastrointest Cancer Res 2008;2:S16-9.
37. Bai J, Demirjian A, Sui J, Marasco W, Callery MP. Histone deacetylase inhibitor trichostatin a and proteasome inhibitor ps-341 synergistically induce apoptosis in pancreatic cancer cells. Biochem Biophys Res Commun 2006;348:1245-53. (Pubitemid 44291339)
38. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002;2:897-909. (Pubitemid 37328891)
39. Ouaissi M, Ouaissi A. Histone deacetylase enzymes as potential drug targets in cancer and parasitic diseases. J Biomed Biotechnol 2006;2006:13474.
40. Donadelli M, Costanzo C, Faggioli L, Scupoli MT, Moore PS, Bassi C, et al. Trichostatin a, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. Mol Carcinog 2003;38:59-69. (Pubitemid 37255141)
41. Shao W, Growney JD, Feng Y, O'Connor G, Pu M, Zhu W, et al: Activity of deacetylase inhibitor panobinostat (lbh589) in cutaneous t-cell lymphoma models: defining molecular mechanisms of resistance. Int J Cancer. 127:2199-2208.
42. Atadja P. Development of the pan-dac inhibitor panobinostat (lbh589): successes and challenges. Cancer Lett 2009;280:233-41.
43. Maiso P, Carvajal-Vergara X, Ocio EM, Lopez-Perez R, Mateo G, Gutierrez N, et al. The histone deacetylase inhibitor lbh589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006;66:5781-9. (Pubitemid 43927132)
44. Han JW, Ahn SH, Park SH, Wang SY, Bae GU, Seo DW, et al. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21waf1/cip1 and gelsolin. Cancer Res 2000;60:6068-74.
45. Kyrylenko S, Kyrylenko O, Suuronen T, Salminen A. Differential regulation of the sir2 histone deacetylase gene family by inhibitors of class i and ii histone deacetylases. Cell Mol Life Sci 2003;60:1990-7. (Pubitemid 37222594)
46. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-84. (Pubitemid 44348499)